A randomized, open labeled, active-controlled trial of 24-week versus 48-week courses of peg-interferon alpha plus ribavirin for genotype-1 infected chronic hepatitis C patients
Phase of Trial: Phase IV
Latest Information Update: 01 Jun 2008
At a glance
- Drugs Peginterferon alfa-2a (Primary) ; Ribavirin (Primary)
- Indications Hepatitis C
- Focus Therapeutic Use
- 01 Jun 2008 Results have been published.
- 24 Mar 2008 New trial record.